[go: up one dir, main page]

NO20050668L - 7,8,9,10-tetrahydro-6H-azepino6,7,8,9-tetrahydro-pyrido og 2,3-dihydro-2H-pyrrolo [2,1-B]-kinazolinon-derivater - Google Patents

7,8,9,10-tetrahydro-6H-azepino6,7,8,9-tetrahydro-pyrido og 2,3-dihydro-2H-pyrrolo [2,1-B]-kinazolinon-derivater

Info

Publication number
NO20050668L
NO20050668L NO20050668A NO20050668A NO20050668L NO 20050668 L NO20050668 L NO 20050668L NO 20050668 A NO20050668 A NO 20050668A NO 20050668 A NO20050668 A NO 20050668A NO 20050668 L NO20050668 L NO 20050668L
Authority
NO
Norway
Prior art keywords
tetrahydro
pyrido
pyrrolo
dihydro
azepino6
Prior art date
Application number
NO20050668A
Other languages
English (en)
Inventor
Ralf Koberstein
Thomas Weller
Walter Fischli
Thierry Sifferlen
Martine Clozel
Hamed Aissaoui
Original Assignee
Actelion Pharmaceuticals Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Actelion Pharmaceuticals Ltd filed Critical Actelion Pharmaceuticals Ltd
Publication of NO20050668L publication Critical patent/NO20050668L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • Diabetes (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Pain & Pain Management (AREA)
  • Anesthesiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Det beskrives nye 7,8,9,10-tetrahydro-6W-azepino-, 6,7,8,9-tetrahydro-pyrido- og 2,3-dihydro-2W-pyrrolo[2,l-fe]-kina2olinoh-derivater med fonnel (I) og anvendelse av dem som aktive bestanddeler ved fremstilling av farmasøytiske preparater. Det beskrives også beslektede aspekter omfattende fremgangsmåter for fremstilling av forbindelsene, farmasøytiske preparater inneholdende én eller flere av forbindelsene og spesielt anvendelse av dem som oreksin-reseptorantagonister.
NO20050668A 2002-07-09 2005-02-08 7,8,9,10-tetrahydro-6H-azepino6,7,8,9-tetrahydro-pyrido og 2,3-dihydro-2H-pyrrolo [2,1-B]-kinazolinon-derivater NO20050668L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP0207608 2002-07-09
PCT/EP2003/007297 WO2004004733A1 (en) 2002-07-09 2003-07-08 7,8,9,10-tetrahydro-6h-azepino, 6,7,8,9-tetrahydro-pyrido and 2,3-dihydro-2h-pyrrolo[2,1-b]-quinazolinone derivatives

Publications (1)

Publication Number Publication Date
NO20050668L true NO20050668L (no) 2005-04-05

Family

ID=30011039

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20050668A NO20050668L (no) 2002-07-09 2005-02-08 7,8,9,10-tetrahydro-6H-azepino6,7,8,9-tetrahydro-pyrido og 2,3-dihydro-2H-pyrrolo [2,1-B]-kinazolinon-derivater

Country Status (16)

Country Link
US (1) US7067519B2 (no)
EP (1) EP1521583B1 (no)
JP (1) JP4498922B2 (no)
CN (1) CN1556705B (no)
AU (1) AU2003246657A1 (no)
CA (1) CA2460051A1 (no)
DE (1) DE60311101T2 (no)
ES (1) ES2278197T3 (no)
IL (1) IL166100A0 (no)
MX (1) MXPA04002269A (no)
NO (1) NO20050668L (no)
NZ (1) NZ538029A (no)
PL (1) PL373223A1 (no)
RU (1) RU2005103398A (no)
WO (1) WO2004004733A1 (no)
ZA (1) ZA200500026B (no)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7538109B2 (en) 2003-04-28 2009-05-26 Actelion Pharmaceuticals Ltd Quinoxalin-3-one derivatives as orexin receptor antagonists
US7678150B2 (en) * 2004-06-15 2010-03-16 Tornier Sas Total shoulder prosthesis of an inverted type
WO2008008517A2 (en) 2006-07-14 2008-01-17 Merck & Co., Inc. Bridged diazepan orexin receptor antagonists
ATE458740T1 (de) * 2006-08-28 2010-03-15 Actelion Pharmaceuticals Ltd 1,4,5,6,7,8-hexahydro-1,2,5-triaza-azulen- derivate als orexinrezeptor-antagonisten
PE20081229A1 (es) 2006-12-01 2008-08-28 Merck & Co Inc Antagonistas de receptor de orexina de diazepam sustituido
ATE545647T1 (de) 2006-12-22 2012-03-15 Actelion Pharmaceuticals Ltd 5,6,7,8-tetrahydro-imidazoä1,5-aüpyrazinderivat
AU2008255005B2 (en) 2007-05-18 2013-05-02 Merck Sharp & Dohme Corp. OXO bridged diazepan orexin receptor antagonists
WO2008150364A1 (en) 2007-05-23 2008-12-11 Merck & Co., Inc. Cyclopropyl pyrrolidine orexin receptor antagonists
WO2008147518A1 (en) 2007-05-23 2008-12-04 Merck & Co., Inc. Pyridyl piperidine orexin receptor antagonists
EP2161266A1 (en) 2008-08-22 2010-03-10 EVOTEC Neurosciences GmbH Benzofuran derivatives as orexin receptor antagonists
EP2348857B1 (en) 2008-10-22 2016-02-24 Merck Sharp & Dohme Corp. Novel cyclic benzimidazole derivatives useful anti-diabetic agents
AU2009309037A1 (en) 2008-10-31 2010-05-06 Merck Sharp & Dohme Corp. Novel cyclic benzimidazole derivatives useful anti-diabetic agents
KR101859409B1 (ko) * 2009-10-23 2018-05-18 얀센 파마슈티카 엔.브이. 오렉신 수용체 조절제로서의 이치환된 옥타하이드로피롤로［3,4-ｃ］피롤
US9062044B2 (en) 2009-10-23 2015-06-23 Janssen Pharmaceutica Nv Disubstituted octahydropyrrolo[3,4-c]pyrroles as orexin receptor modulators
US8680275B2 (en) 2009-10-23 2014-03-25 Janssen Pharmaceutica Nv Fused heterocyclic compounds as orexin receptor modulators
US8895596B2 (en) 2010-02-25 2014-11-25 Merck Sharp & Dohme Corp Cyclic benzimidazole derivatives useful as anti-diabetic agents
WO2011138265A2 (en) 2010-05-03 2011-11-10 Evotec Ag Indole and indazole derivatives as orexin receptor antagonists
WO2011138266A1 (en) 2010-05-03 2011-11-10 Evotec Ag Indolizine and imidazopyridine derivatives as orexin receptor antagonists
MY159058A (en) 2011-02-25 2016-12-15 Merck Sharp & Dohme Novel cyclic azabenzimidazole derivatives useful as anti-diabetic agent
US9586962B2 (en) 2011-04-20 2017-03-07 Janssen Pharmaceutica Nv Disubstituted octahydropyrrolo [3,4-C] pyrroles as orexin receptor modulators
ES2562903T3 (es) * 2011-07-13 2016-03-09 Santen Pharmaceutical Co., Ltd Nuevo compuesto que tiene actividad inhibidora de PARP
AR088352A1 (es) 2011-10-19 2014-05-28 Merck Sharp & Dohme Antagonistas del receptor de 2-piridiloxi-4-nitrilo orexina
US9440982B2 (en) 2012-02-07 2016-09-13 Eolas Therapeutics, Inc. Substituted prolines/piperidines as orexin receptor antagonists
NZ628491A (en) 2012-02-07 2016-06-24 Eolas Therapeutics Inc Substituted prolines / piperidines as orexin receptor antagonists
EP2880028B1 (en) 2012-08-02 2020-09-30 Merck Sharp & Dohme Corp. Antidiabetic tricyclic compounds
JP2016516004A (ja) 2013-02-22 2016-06-02 メルク・シャープ・アンド・ドーム・コーポレーションＭｅｒｃｋ Ｓｈａｒｐ ＆ Ｄｏｈｍｅ Ｃｏｒｐ． 抗糖尿病二環式化合物
WO2014139388A1 (en) 2013-03-14 2014-09-18 Merck Sharp & Dohme Corp. Novel indole derivatives useful as anti-diabetic agents
WO2015051496A1 (en) 2013-10-08 2015-04-16 Merck Sharp & Dohme Corp. Antidiabetic tricyclic compounds
JP6663909B2 (ja) 2014-08-13 2020-03-13 エオラス セラピューティクス， インコーポレイテッド オレキシンレセプターモジュレーターとしてのジフルオロピロリジン
SI3414241T1 (sl) 2016-02-12 2022-10-28 Astrazeneca Ab Halo-substituitani piperidini kot modulatorji receptorja oreksina
PT3426251T (pt) 2016-03-10 2022-07-27 Janssen Pharmaceutica Nv Métodos de tratamento da depressão utilizando antagonistas dos recetores de orexina-2
US20190151304A1 (en) 2016-05-10 2019-05-23 Inserm (Institut National De La Santé Et De La Rechercjae Médicale Methods and pharmaceutical compositions for the treatment of autoimmune inflammatory
US11072602B2 (en) 2016-12-06 2021-07-27 Merck Sharp & Dohme Corp. Antidiabetic heterocyclic compounds
US10968232B2 (en) 2016-12-20 2021-04-06 Merck Sharp & Dohme Corp. Antidiabetic spirochroman compounds
JP7498108B2 (ja) 2017-08-03 2024-06-11 ガレクティン・サイエンシーズ・リミテッド・ライアビリティ・カンパニー 医学的障害の予防および治療のための化合物およびその使用
US12071434B2 (en) 2018-12-12 2024-08-27 Takeda Pharmaceutical Company Limited Heterocyclic compound
WO2025224168A1 (en) 2024-04-24 2025-10-30 Idorsia Pharmaceuticals Ltd Aryl sulfone and sulfanone derivatives as orexin receptor modulators

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HU173438B (hu) * 1975-11-27 1979-05-28 Chinoin Gyogyszer Es Vegyeszet Sposob poluchenija novykh proizvodnykh 4-okso-1,6,7,8-/tetragidro-4h-pirido/1,2/pirimidina s zaderzhivajuhhejj vozgoranie aktivnot'ju i protivosvertivajuhhem effektom
HU191192B (en) * 1982-11-16 1987-01-28 Chinoin Gyogyszer Es Vegyeszeti Termekek Gyara Rt,Hu Process for producing new azepino /1,2-a/ pyrimidine derivatives of bronchodilating activity and acid additional salts thereof and pharmaceiutical compositions containing them
US4678499A (en) * 1985-03-11 1987-07-07 E. I. Du Pont De Nemours And Company Herbicidal sulfonamides
US5753664A (en) * 1995-03-16 1998-05-19 Takeda Chemical Industries, Ltd. Heterocyclic compounds, their production and use
WO1998025932A1 (en) * 1996-12-09 1998-06-18 Warner-Lambert Company Antibacterial agents
AR016817A1 (es) 1997-08-14 2001-08-01 Smithkline Beecham Plc Derivados de fenilurea o feniltiourea, procedimiento para su preparacion, coleccion de compuestos, compuestos intermediarios, composicion farmaceutica,metodo de tratamiento y uso de dichos compuestos para la manufactura de un medicamento
ES2196806T3 (es) 1998-05-08 2003-12-16 Smithkline Beecham Plc Derivados de fenilurea y de feniltiourea.
WO2000047576A1 (en) 1999-02-12 2000-08-17 Smithkline Beecham Plc Cinnamide derivatives as orexin-1 receptors antagonists
AU2804400A (en) 1999-02-12 2000-08-29 Smithkline Beecham Plc Phenyl urea and phenyl thiourea derivatives as orexin receptor antagonists
JP2002536447A (ja) * 1999-02-12 2002-10-29 スミスクライン・ビーチャム・パブリック・リミテッド・カンパニー フェニル尿素およびフェニルチオ尿素誘導体
DE19906975B4 (de) * 1999-02-19 2004-04-15 Lts Lohmann Therapie-Systeme Ag Arzneiform zur Behandlung von Alzheimer'scher Demenz
WO2001066099A2 (en) * 2000-03-06 2001-09-13 Astrazeneca Ab Use of quinazoline derivatives as angiogenesis inhibitors
EP1288202A4 (en) 2000-05-11 2003-07-02 Banyu Pharma Co Ltd N-acyltetrahydroisoquinoline derivatives
AU2001272476A1 (en) 2000-06-16 2001-12-24 Smithkline Beecham Plc Piperidines for use as orexin receptor antagonists
AU2002224885A1 (en) * 2000-11-28 2002-06-11 Smithkline Beecham Plc Morpholine derivatives as antagonists of orexin receptors
GB0121214D0 (en) * 2001-08-31 2001-10-24 Btg Int Ltd Synthetic method
JP2005506350A (ja) * 2001-10-18 2005-03-03 ベーリンガー インゲルハイム ファーマシューティカルズ インコーポレイテッド サイトカイン阻害薬としての１，４−二置換ベンゾ−縮合尿素化合物
US6676976B2 (en) * 2002-03-21 2004-01-13 Council Of Scientific And Industrial Research Process for the production of vasicine

Also Published As

Publication number Publication date
AU2003246657A1 (en) 2004-01-23
NZ538029A (en) 2006-08-31
EP1521583B1 (en) 2007-01-10
DE60311101D1 (de) 2007-02-22
RU2005103398A (ru) 2006-06-27
CA2460051A1 (en) 2004-01-15
ES2278197T3 (es) 2007-08-01
DE60311101T2 (de) 2007-06-21
EP1521583A1 (en) 2005-04-13
IL166100A0 (en) 2006-01-15
CN1556705A (zh) 2004-12-22
US7067519B2 (en) 2006-06-27
MXPA04002269A (es) 2004-06-29
JP4498922B2 (ja) 2010-07-07
US20050009852A1 (en) 2005-01-13
CN1556705B (zh) 2010-04-28
WO2004004733A1 (en) 2004-01-15
JP2005532381A (ja) 2005-10-27
PL373223A1 (en) 2005-08-22
ZA200500026B (en) 2005-10-20

Similar Documents

Publication Publication Date Title
NO20050668L (no) 7,8,9,10-tetrahydro-6H-azepino6,7,8,9-tetrahydro-pyrido og 2,3-dihydro-2H-pyrrolo [2,1-B]-kinazolinon-derivater
NO20050932L (no) 1-pyridin-4-yl-ureaderivater
NO20051102L (no) Sulfonylamino-eddiksyre-derivater
NO20032905D0 (no) Nye benzodiazepiner og beslektede heterocykliske derivater som er anvendelige som orexinreseptorantagonister
ATE301653T1 (de) Pyrazolopyridine
ATE286500T1 (de) 1,2,3,4-tetrahydroisochinolin-derivate
BRPI0408681A (pt) compostos, composições farmacêuticas, uso de um derivado da 1,2,3,4-tetraidroisoquinolina, método para tratar ou prevenir doenças, processo para a manufatura de composições farmacêuticas, e, uso de um ou mais compostos
NO20042844L (no) 4-(piperidyl- og pyrrolidyl-alkyl-ureido)-kinoliner som uprotensin II reseptor-antagonister
DE60204452D1 (de) Pyrazolo[1,5]pyridinderivate
ATE332301T1 (de) Antivirale pyrazolopyridin verbindungen
WO2003095455A3 (en) Substituted pyrazolopyrimidines
NO20034230L (no) 1,2,3,4-tetrahydroisokinolin-derivater som urotensin II reseptor-antagonister
NO20063231L (no) Pyrido[2,3-D]pyrimidin-2,4-diaminer som PDE 2 inhibitorer
NO20050290L (no) Nye tetrahydropyridin-derivater som renin-inhibitorer
ATE300541T1 (de) Pyrazolopyridinderivate
ECSP045378A (es) Derivados novedosos de diazabiciclononeno
NO20004089L (no) Nye triazolo(4,5-d)pyrimidinforbindelser
ATE383345T1 (de) Quinoxalin-3-on-verdindungen als orexin-rezeptor antagonisten.
NO20061395L (no) Nye pyridinderivater
NO20055623L (no) Azabicyklononenderivater
BR0316724A (pt) Compostos, uso de um ou mais compostos, e, processo para a fabricação de composições farmacêuticas
NO20055624L (no) Tropanderivater og deres anvendelse som Ace-inhibitorer
WO2002024665A8 (en) Arylalkane-sulfonamides having endothelin-antagonist activity
NO20040821L (no) 3-substituerte 6,7-dihydroksytetrahydroisokinolinderivater for andvendelse som antibakterielle midler.
ATE373000T1 (de) Pyrazolopyridin-derivate als antiherpesmittel